MT Newswires
Gilead Says Single Tablet of Bictegravir, Lenacapavir to Treat HIV Meets Primary Goal in Phase 3 Trial
➖
AI Sentiment
Neutral
5/10
- Home
- GILD
GILD
Gilead Sciences Inc.
as of 12-16-2025 3:40pm EST
$119.14
$0.86
-0.72%
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Chart Type:
Time Range:
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 147.6B | IPO Year: | 1992 |
| Target Price: | $127.10 | AVG Volume (30 days): | 7.0M |
| Analyst Decision: | Buy | Number of Analysts: | 20 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 6.42 | EPS Growth: | 6514.05 |
| 52 Week Low/High: | $88.57 - $128.70 | Next Earning Date: | 10-30-2025 |
| Revenue: | $29,087,000,000 | Revenue Growth: | 2.79% |
| Revenue Growth (this year): | 3.63% | Revenue Growth (next year): | 2.97% |
AI-Powered GILD Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 75.00%
75.00%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Gilead Sciences Inc. (GILD)
Kramer Kelly A.
Sell
Director
GILD Nov 28, 2025
Avg Cost/Share
$127.10
Shares
2,805
Total Value
$356,515.50
Owned After
1,339
SEC Form 4
O'Day Daniel Patrick
Sell
Chairman & CEO
GILD Nov 28, 2025
Avg Cost/Share
$126.38
Shares
10,000
Total Value
$1,265,443.77
Owned After
571,203
Bluestone Jeffrey
Sell
Director
GILD Nov 28, 2025
Avg Cost/Share
$125.08
Shares
5,000
Total Value
$625,400.00
Owned After
8,920
SEC Form 4
Kramer Kelly A.
Sell
Director
GILD Nov 26, 2025
Avg Cost/Share
$127.11
Shares
2,806
Total Value
$356,670.66
Owned After
1,339
SEC Form 4
Dickinson Andrew D
Sell
Chief Financial Officer
GILD Nov 17, 2025
Avg Cost/Share
$125.23
Shares
2,500
Total Value
$313,075.00
Owned After
154,555
SEC Form 4
Mercier Johanna
Sell
Chief Commercial Officer
GILD Nov 17, 2025
Avg Cost/Share
$126.04
Shares
28,000
Total Value
$3,524,173.42
Owned After
107,193
Telman Deborah H
Sell
EVP, Corporate Affairs & GC
GILD Nov 12, 2025
Avg Cost/Share
$123.07
Shares
53,646
Total Value
$6,590,487.43
Owned After
43,676
O'Day Daniel Patrick
Sell
Chairman & CEO
GILD Oct 28, 2025
Avg Cost/Share
$119.18
Shares
10,000
Total Value
$1,193,925.67
Owned After
571,203
Dickinson Andrew D
Sell
Chief Financial Officer
GILD Oct 15, 2025
Avg Cost/Share
$118.08
Shares
2,500
Total Value
$295,200.00
Owned After
154,555
SEC Form 4
Mercier Johanna
Sell
Chief Commercial Officer
GILD Oct 15, 2025
Avg Cost/Share
$118.08
Shares
3,000
Total Value
$354,240.00
Owned After
107,193
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Kramer Kelly A. | GILD | Director | Nov 28, 2025 | Sell | $127.10 | 2,805 | $356,515.50 | 1,339 | |
| O'Day Daniel Patrick | GILD | Chairman & CEO | Nov 28, 2025 | Sell | $126.38 | 10,000 | $1,265,443.77 | 571,203 | |
| Bluestone Jeffrey | GILD | Director | Nov 28, 2025 | Sell | $125.08 | 5,000 | $625,400.00 | 8,920 | |
| Kramer Kelly A. | GILD | Director | Nov 26, 2025 | Sell | $127.11 | 2,806 | $356,670.66 | 1,339 | |
| Dickinson Andrew D | GILD | Chief Financial Officer | Nov 17, 2025 | Sell | $125.23 | 2,500 | $313,075.00 | 154,555 | |
| Mercier Johanna | GILD | Chief Commercial Officer | Nov 17, 2025 | Sell | $126.04 | 28,000 | $3,524,173.42 | 107,193 | |
| Telman Deborah H | GILD | EVP, Corporate Affairs & GC | Nov 12, 2025 | Sell | $123.07 | 53,646 | $6,590,487.43 | 43,676 | |
| O'Day Daniel Patrick | GILD | Chairman & CEO | Oct 28, 2025 | Sell | $119.18 | 10,000 | $1,193,925.67 | 571,203 | |
| Dickinson Andrew D | GILD | Chief Financial Officer | Oct 15, 2025 | Sell | $118.08 | 2,500 | $295,200.00 | 154,555 | |
| Mercier Johanna | GILD | Chief Commercial Officer | Oct 15, 2025 | Sell | $118.08 | 3,000 | $354,240.00 | 107,193 |
Latest Gilead Sciences Inc. News
GILD Breaking Stock News: Dive into GILD Ticker-Specific Updates for Smart Investing
Business Wire
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
📈
AI Sentiment
Highly Positive
9/10
Simply Wall St.
Is Earlier Yescarta Use in Lymphoma Altering The Investment Case For Gilead Sciences (GILD)?
📈
AI Sentiment
Highly Positive
8/10
Investor's Business Daily
Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak
⚠️
AI Sentiment
Highly Negative
1/10
Zacks
Kymera's Eczema Drug Gets Fast Track Designation in the United States
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
Morgan Stanley Adjusts PT on Gilead Sciences to $151 From $147, Maintains Overweight Rating
📊
AI Sentiment
Positive
6/10
MT Newswires
Arcus Biosciences Discontinuing Gastric, Esophogeal Cancer Candidate Trial; Shares Fall
➖
AI Sentiment
Neutral
4/10
BioPharma Dive
Arcus cancels work on Gilead-partnered cancer combo after trial setback
📉
AI Sentiment
Negative
2/10
Compare GILD vs Leading Stocks
See how GILD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GILD Gilead Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.